The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients
Abstract
Adrenocortical carcinoma (ACC) is a rare cancer with poor prognosis. Local and distant recurrences occur in a subset of tumors classified as ‘aggressive’ ACC (aACC), as opposed to ‘non-aggressive’ ACC (naACC). In this study, we investigated whether tissue and serum microRNAs (miRNAs) are predictive of ACC prognosis. Tissue miRNA expression profiles were determined using microarrays in a test series of six adrenocortical adenomas (ACAs), six naACCs, and six aACCs. Eight miRNAs were selected for further validation by quantitative RT-PCR (ten ACAs, nine naACCs, nine aACCs, and three normal adrenals). Serum levels of five miRNAs were measured in samples from 56 subjects (19 healthy controls (HC), 14 ACA, nine naACC, and 14 aACC patients). MiR-195 and miR-335 levels were significantly decreased in both tumor and serum samples of ACC patients relative to ACA patients or HC. MiR-139-5p and miR-376a levels were significantly increased in aACC compared with naACC patients in tumor samples only. Tissue miR-483-5p was markedly upregulated in a majority of ACC compared with ACA patients or HC, but most importantly, serum miR-483-5p was detected only in aACC patients. High circulating levels of miR-483-5p or low circulating levels of miR-195 were associated with both shorter recurrence-free survival (P=0.0004 and P=0.0014 respectively) and shorter overall survival (P=0.0005 and P=0.0086 respectively). In conclusion, this study reports for the first time that circulating miR-483-5p and miR-195 are promising noninvasive biomarkers with a highly specific prognostic value for the clinical outcome of ACC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors
Weiss, L. M. (1984) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198403000-00001 · Cited by 920 · cited 3×
“Malignancy was assessed according to Weiss criteria (Weiss 1984) by a single experienced pathologist, and tumor staging was performed using the European Network for the Study of Adrenal Tumors classification (Fassnacht et al. 2009).”
Hu, Z., Chen, X., Zhao, Y., Tian, T., Jin, G., Shu, Y., Chen, Y., Xu, L., Zen, K., Zhang, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9342 · Cited by 798
Abiven, G., Coste, J., Groussin, L., Anract, P., Tissier, F., Legmann, P., Dousset, B., Bertagna, X., & Bertherat, J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2730 · Cited by 435 · cited 1×
“Follow-up was performed as described previously (Abiven et al. 2006).”
Self-citationMolecular classification and prognostication of adrenocortical tumors by transcriptome profiling
Giordano, T. J., Kuick, R., Else, T., Gauger, P. G., Vinco, M., Bauersfeld, J., Sanders, D., Thomas, D. G., Doherty, G., & Hammer, G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1067 · Cited by 401
Adrenocortical carcinoma: a clinician’s update
Fassnacht, M., Libé, R., Kroiss, M., & Allolio, B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.235 · Cited by 396 · cited 1×
“While surgical resection may cure some patients with localized disease, most patients present with advanced disease or develop local recurrence and distant metastasis after surgery (Fassnacht et al. 2011).”
Self-citationde Reyniès, A., Assié, G., Rickman, D. S., Tissier, F., Groussin, L., René-Corail, F., Dousset, B., Bertagna, X., Clauser, E., & Bertherat, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5678 · Cited by 382 · cited 3×
“More recently, two-gene malignancy signature has been associated with clinical outcome of ACC patients (de Reynies et al. 2009).”
Self-citationDoghman, M., Wakil, A. E., Cardinaud, B., Thomas, E., Wang, J., Zhao, W., Peralta-Del Valle, M. H. C., Figueiredo, B. C., Zambetti, G. P., & Lalli, E. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3970 · Cited by 221 · cited 3×
“2009b, Doghman et al. 2010, Ozata et al. 2011, Patterson et al. 2011, Schmitz et al. 2011), our RT-qPCR analyses revealed that miR-195 and miR-335 were downregulated in ACC (nZ30) compared with ACA (nZ16) tumor tissues. A trend toward an increase in miR-483-5p in ACC tissues compared with ACA was first reported by Soo…”
Tömböl, Z., Szabó, P. M., Molnár, V., Wiener, Z., Tölgyesi, G., Horányi, J., Riesz, P., Reismann, P., Patócs, A., Likó, I., et al. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0096 · Cited by 176 · cited 3×
“Profiling miRNA expression in benign and malignant adrenocortical tumors led to the identification of several deregulated miRNAs in ACC compared with ACA (Soon et al. 2009b, Tombol et al. 2009, Doghman et al. 2010, Ozata et al. 2011, Patterson et al. 2011, Schmitz et al. 2011).”
BackgroundMicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy
Patterson, E. E., Holloway, A. K., Weng, J., Fojo, T., & Kebebew, E. (2011) · Cancer · doi:10.1002/cncr.25724 · Cited by 171 · cited 5×
“Previous miRNA expression profiling of benign and malignant adrenocortical tumors provided potential diagnostic and prognostic tools for the disease (Soon et al. 2009b, Tombol et al. 2009, Ozata et al. 2011, Patterson et al. 2011, Schmitz et al. 2011).”
Influential
Cited by
Fassnacht, M., Dekkers, O. M., Else, T., Baudin, E., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assie, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 961
Self-citationIntegrated genomic characterization of adrenocortical carcinoma
Assié, G., Letouzé, E., Fassnacht, M., Jouinot, A., Luscap, W., Barreau, O., Omeiri, H., Rodriguez, S., Perlemoine, K., René-Corail, F., et al. (2014) · Nature Genetics · doi:10.1038/ng.2953 · Cited by 732
Self-citationUpdate in Adrenocortical Carcinoma
Fassnacht, M., Kroiss, M., & Allolio, B. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3020 · Cited by 414
60 YEARS OF POMC: Adrenal and extra-adrenal functions of ACTH
Gallo-Payet, N. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-15-0257 · Cited by 98
Genetics of tumors of the adrenal cortex
Bonnet-Serrano, F., & Bertherat, J. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0361 · Cited by 80
Self-citationPapotti, M., Duregon, E., Volante, M., & McNicol, A. M. (2014) · Endocrine Pathology · doi:10.1007/s12022-013-9291-6 · Cited by 33
Metadata
- Authors
- Chabre, O., Libé, R., Assie, G., Barreau, O., Bertherat, J., Bertagna, X., Feige, J.-J., & Cherradi, N.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2013-06-11
- Volume
- 20
- Issue
- 4
- Pages
- 579-594
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2145602376
- Cited by
- 189
- References
- 9
- FWCI
- 19.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.